GT201100011DA - Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos - Google Patents

Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos

Info

Publication number
GT201100011DA
GT201100011DA GT201100011DA GT201100011A GT201100011DA GT 201100011D A GT201100011D A GT 201100011DA GT 201100011D A GT201100011D A GT 201100011DA GT 201100011 A GT201100011 A GT 201100011A GT 201100011D A GT201100011D A GT 201100011DA
Authority
GT
Guatemala
Prior art keywords
antibodies
same
usself
neutralizing antibodies
fragments
Prior art date
Application number
GT201100011DA
Other languages
English (en)
Spanish (es)
Inventor
Lanzavecchia Antonio
Macagno Annalisa
Original Assignee
Inst Res Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201100011D(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Res Biomedicine filed Critical Inst Res Biomedicine
Publication of GT201100011DA publication Critical patent/GT201100011DA/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A01D34/71—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis with means for discharging mown material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D2101/00—Lawn-mowers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GT201100011DA 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos GT201100011DA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8133408P 2008-07-16 2008-07-16

Publications (1)

Publication Number Publication Date
GT201100011DA true GT201100011DA (es) 2017-09-20

Family

ID=41550776

Family Applications (4)

Application Number Title Priority Date Filing Date
GT201100011DA GT201100011DA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos
GT201100011CM GT201100011CA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
GT201100011AK GT201100011AA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
GT201100011BL GT201100011BA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalorivus humano y uso de los mismos

Family Applications After (3)

Application Number Title Priority Date Filing Date
GT201100011CM GT201100011CA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
GT201100011AK GT201100011AA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
GT201100011BL GT201100011BA (es) 2008-07-16 2011-01-14 Anticuerpos neutralizantes de citomegalorivus humano y uso de los mismos

Country Status (31)

Country Link
US (21) US8603480B2 (fr)
EP (3) EP2352759B1 (fr)
JP (5) JP5422649B2 (fr)
KR (1) KR101356350B1 (fr)
CN (3) CN106924729B (fr)
AU (1) AU2009272284C1 (fr)
BR (1) BRPI0916443A2 (fr)
CA (2) CA3022196A1 (fr)
CL (3) CL2011000084A1 (fr)
CO (1) CO6351801A2 (fr)
CR (2) CR20160355A (fr)
CU (1) CU23953B1 (fr)
DK (2) DK3009449T3 (fr)
EA (1) EA031177B1 (fr)
EC (2) ECSP11010826A (fr)
ES (2) ES2682596T3 (fr)
GT (4) GT201100011DA (fr)
HK (1) HK1220981A1 (fr)
HN (1) HN2011000161A (fr)
IL (7) IL210356A (fr)
MA (1) MA32561B1 (fr)
MX (5) MX343490B (fr)
NZ (5) NZ619953A (fr)
PE (7) PE20141434A1 (fr)
PH (1) PH12015500782A1 (fr)
PL (2) PL3009449T3 (fr)
PT (2) PT2352759T (fr)
SG (3) SG10201608381SA (fr)
UA (1) UA106354C2 (fr)
WO (1) WO2010007533A2 (fr)
ZA (1) ZA201600335B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
ES2682596T3 (es) 2008-07-16 2018-09-21 Institute For Research In Biomedicine Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos
MX2012007489A (es) 2009-12-23 2012-11-29 4Antibody Ag Miembros enlazadores para citomegalovirus.
CA2839420C (fr) * 2010-06-16 2023-06-13 Lawrence M. Kauvar Anticorps humains a affinite elevee contre la proteine gb du cytomegalovirus (cmv) humain
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
EP2590670B1 (fr) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Procédé pour induire une réponse immunitaire par administration d'arn
ES2938866T3 (es) 2010-08-31 2023-04-17 Glaxosmithkline Biologicals Sa Liposomas pegilados para la administración de ARN que codifica para inmunógeno
KR20130112879A (ko) * 2010-09-29 2013-10-14 제넨테크, 인크. 항체 조성물 및 사용 방법
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
WO2013006838A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions de combinaisons immunogènes et utilisations de celles-ci
EP2831119A1 (fr) * 2012-03-28 2015-02-04 F. Hoffmann-La Roche AG Anticorps idiotypiques anti-hcmv et leurs utilisations
ES2719720T3 (es) 2012-07-27 2019-07-12 Hope City Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV
WO2014028865A1 (fr) * 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions et procédés de détection d'activation de complément
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
EP3048114A1 (fr) * 2015-01-22 2016-07-27 Novartis AG Antigènes du cytomégalovirus et leurs utilisations
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
WO2017044895A2 (fr) 2015-09-10 2017-03-16 City Of Hope Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés
CN105296588A (zh) * 2015-10-16 2016-02-03 常州市第一人民医院 一种检测肾移植患者在术后感染巨细胞病毒危害程度的方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
EP3426676A1 (fr) 2016-03-11 2019-01-16 Pfizer Inc Polypeptide gb de cytomégalovirus humain
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US20200377606A1 (en) 2016-04-18 2020-12-03 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
WO2017196819A2 (fr) * 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Anticorps anti-cytomégalovirus humain (hcmv) largement neutralisant et leurs procédé d'utilisation
MY196869A (en) 2016-06-27 2023-05-05 Univ California Cancer treatment combinations
EP3497232A1 (fr) 2016-08-12 2019-06-19 Streck, Inc. Contrôles de référence moléculaires
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
EP3609521A4 (fr) * 2017-04-14 2021-06-16 University of Massachusetts Ciblage de récepteurs de tropisme cellulaire pour inhiber une infection par le cytomégalovirus
WO2018193307A1 (fr) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus modifiées et complexes stabilisés
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
WO2019183375A1 (fr) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Agents d'anticorps reconnaissant spécifiquement le transporteur monocarboxylate 4 et leurs utilisations
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
US11396546B2 (en) 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
CA3116175A1 (fr) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Proteines de cytomegalovirus modifiees et complexes stabilises
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
WO2020208082A1 (fr) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de traitement des maladies liées au cytomégalovirus
CN118465272A (zh) * 2019-12-04 2024-08-09 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
WO2021191836A1 (fr) * 2020-03-27 2021-09-30 Glaxosmithkline Biologicals Sa Anticorps de liaison à pentamère de hcvm
TW202413391A (zh) 2020-06-21 2024-04-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3230585A1 (fr) * 2021-09-03 2023-03-09 Domenico Tortorella Anticorps anti-hcmv et leurs fragments de liaison a l'antigene
CN118652325A (zh) * 2022-10-21 2024-09-17 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3581400D1 (de) 1984-09-28 1991-02-21 Teijin Ltd Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
KR910000736B1 (ko) 1985-12-06 1991-02-06 데이진 가부시키가이샤 사이토메갈로 바이러스에 대한 사람·모노클로날 항체와 그 제조방법
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (fr) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Anticorps monoclonaux specifiques contre une glycoproteine de cytomegalovirus
WO1991005876A1 (fr) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Cocktail d'anticorps monoclonaux specifiques du cytomegalovirus humain
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
DE69227623T2 (de) 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
ATE179613T1 (de) 1993-01-21 1999-05-15 Erna Moeller Verhütung und behandlung von zytomegalovirus mittels aminopeptidase
WO1994016730A1 (fr) 1993-01-28 1994-08-04 Sandoz Pharmaceutical Corporation Anticorps monoclonaux humains contre le cytomegalovirus
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (fr) 1994-07-26 1997-01-15 Biotest Ag Polypeptides et protéines fusionnées contenant la structure à lecture ouverte UL57 ou la séquence C-terminal de la protéine pp150 de tégument de HCMV, oligonucléotides et trousses diagnostiques correspondantes
US5502652A (en) 1994-08-24 1996-03-26 Hoggatt; Austin C. Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
DK0960336T3 (da) 1996-07-12 2003-02-10 Organon Teknika Bv Peptidreagens til påvisning af humant cytomelagovirus (CMV)
US6291437B1 (en) 1996-08-14 2001-09-18 The Wistar Institute Of Anatomy And Biology Methods and compositions for retarding the development of atherosclerotic lesions
US7504493B2 (en) * 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
EP1003841A4 (fr) 1997-01-30 2002-04-17 Cedars Sinai Medical Center Creation d'une lignee cellulaire lymphomateuse a hsv-8+, virus produit, anticorps, methode diagnostique et trousse pour detecter l'infection par le hsv-8
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1998057993A1 (fr) 1997-06-19 1998-12-23 The Regents Of The University Of California Immunoglobuline secretoire produite par des cellules d'un seul type, et procedes de fabrication et d'utilisation de celle-ci
NZ502626A (en) 1997-07-18 2002-09-27 Connaught Lab Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV)
WO1999025858A1 (fr) 1997-11-14 1999-05-27 Connaught Laboratories Limited Vecteurs d'alphavirus pour les vaccins de paramyxovirus
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
JP3764047B2 (ja) 1998-03-12 2006-04-05 ジェネンテック・インコーポレーテッド 網膜ニューロン死の防止及び眼病の治療方法
AU5503899A (en) 1998-06-29 2000-01-17 Wolfgang Bergter Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US20040087001A1 (en) 2001-02-21 2004-05-06 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
CN1188427C (zh) * 2001-12-07 2005-02-09 暨南大学 检测hcmv抗体的重组嵌合肽抗原及其产生方法
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2003085121A2 (fr) 2002-04-01 2003-10-16 Agensys, Inc. Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
TWI270088B (en) 2002-11-29 2007-01-01 Furukawa Electric Co Ltd Insulated wire and resin dispersion
RU2239453C2 (ru) 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US20040228842A1 (en) 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
WO2004078926A2 (fr) 2003-02-28 2004-09-16 Board Of Trustees Operating Michigan State University Marqueurs immunologiques
LT2662390T (lt) 2004-06-21 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas
EP1778862A2 (fr) 2004-07-09 2007-05-02 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Différences de profils d'expression de gènes dans l'intestin
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
EP2284194A1 (fr) 2004-12-21 2011-02-16 AstraZeneca AB Anticorps dirigés contre l'Angiopoiétine 2 et leurs utilisations
DE602005027258D1 (de) 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
EP1895898B1 (fr) 2005-06-29 2011-02-16 Compumedics Limited Ensemble capteur a pont conducteur
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
ATE513034T1 (de) 2005-12-16 2011-07-15 Ribovax Biotechnologies Sa Verfahren zur gewinnung immortalisierter antikörpersezernierender zellen
WO2007094423A1 (fr) 2006-02-15 2007-08-23 Evec Incorporated Anticorps monoclonal humain capable de se lier au cytomegalovirus humain et domaine de liaison antigene de l'anticorps
KR101442209B1 (ko) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
CA2654563A1 (fr) 2006-06-07 2007-12-21 The Trustees Of Princeton University Complexe de proteine de surface du cytomegalovirus destine a etre utilise dans des vaccins et en tant que cible de medicament
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
BRPI0720464A2 (pt) * 2006-12-15 2014-01-14 Ribovax Biotechnologies Sa Anticorpos contra citomegalovírus humano (hcmv)
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (fr) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Procédés de diagnostic et de traitement de maladies provoquées par le cytomégalovirus
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
WO2009024445A1 (fr) 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Anticorps dirigés contre le cytomégalovirus humain (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
WO2010000020A1 (fr) 2008-06-30 2010-01-07 Cathrx Ltd Cathéter
EP2303923B1 (fr) 2008-07-16 2015-06-24 Institute for Research in Biomedicine Anticorps neutralisant les cytomégalovirus humains et leur utilisation
ES2682596T3 (es) 2008-07-16 2018-09-21 Institute For Research In Biomedicine Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos

Also Published As

Publication number Publication date
JP6345753B2 (ja) 2018-06-20
CN102203133A (zh) 2011-09-28
US20160096880A1 (en) 2016-04-07
US9249213B2 (en) 2016-02-02
IL232865A (en) 2016-07-31
AU2009272284B2 (en) 2012-04-05
SG10201706350PA (en) 2017-09-28
CL2016001340A1 (es) 2016-10-28
MX343250B (es) 2016-10-31
NZ591056A (en) 2013-02-22
EP2352759A2 (fr) 2011-08-10
US20130022618A1 (en) 2013-01-24
EP3178845A1 (fr) 2017-06-14
US20180371062A1 (en) 2018-12-27
IL232862A0 (en) 2014-07-31
PE20110413A1 (es) 2011-06-25
US9796772B2 (en) 2017-10-24
PE20141432A1 (es) 2014-10-18
CN106924729B (zh) 2021-03-02
JP6703037B2 (ja) 2020-06-03
US20110268746A1 (en) 2011-11-03
US20180086819A1 (en) 2018-03-29
ES2654543T3 (es) 2018-02-14
NZ603498A (en) 2014-02-28
PL3009449T3 (pl) 2018-09-28
CL2011000084A1 (es) 2011-07-01
HK1220981A1 (zh) 2017-05-19
MX2011000543A (es) 2011-04-27
US20160280769A1 (en) 2016-09-29
IL232861A (en) 2016-06-30
US20150353627A1 (en) 2015-12-10
US20170081391A1 (en) 2017-03-23
NZ603499A (en) 2014-05-30
US20170129940A1 (en) 2017-05-11
US20100092481A1 (en) 2010-04-15
PE20141433A1 (es) 2014-10-19
US8435524B2 (en) 2013-05-07
US8603480B2 (en) 2013-12-10
KR101356350B1 (ko) 2014-01-27
JP5807050B2 (ja) 2015-11-10
JP2018139611A (ja) 2018-09-13
US20160280770A1 (en) 2016-09-29
GT201100011AA (es) 2017-09-14
MX338067B (es) 2016-04-01
IL238421A (en) 2016-06-30
NZ619953A (en) 2015-06-26
AU2009272284C1 (en) 2014-05-15
JP2017055765A (ja) 2017-03-23
PE20141398A1 (es) 2014-10-18
CU20110009A7 (es) 2012-06-21
WO2010007533A3 (fr) 2010-08-12
EA031177B1 (ru) 2018-11-30
PT2352759T (pt) 2018-01-08
US20170129939A1 (en) 2017-05-11
JP2015145412A (ja) 2015-08-13
PE20141434A1 (es) 2014-10-22
US8765132B2 (en) 2014-07-01
US20170334972A1 (en) 2017-11-23
IL232864A (en) 2016-07-31
JP2014087337A (ja) 2014-05-15
MX343490B (es) 2016-11-08
ZA201600335B (en) 2017-11-29
JP2011527902A (ja) 2011-11-10
CO6351801A2 (es) 2011-12-20
EP3009449A1 (fr) 2016-04-20
IL232863A (en) 2016-06-30
PE20140882A1 (es) 2014-07-25
CR20160355A (es) 2016-10-11
IL232863A0 (en) 2014-07-31
JP6062477B2 (ja) 2017-01-18
PH12015500782A1 (en) 2015-12-14
US9527902B2 (en) 2016-12-27
ES2682596T3 (es) 2018-09-21
CL2014001293A1 (es) 2014-12-05
US9221897B2 (en) 2015-12-29
GT201100011BA (es) 2017-09-14
US9803000B1 (en) 2017-10-31
EP2352759B1 (fr) 2017-11-01
US9796771B2 (en) 2017-10-24
CR20110091A (es) 2011-06-24
SG10201608381SA (en) 2016-11-29
CN103980363B (zh) 2017-04-12
IL210356A0 (en) 2011-03-31
CA2730776C (fr) 2018-12-11
US10889632B2 (en) 2021-01-12
MX340315B (es) 2016-07-06
CA2730776A1 (fr) 2010-01-21
US20120128691A1 (en) 2012-05-24
NZ707788A (en) 2016-08-26
CN103980363A (zh) 2014-08-13
AU2009272284A1 (en) 2010-01-21
US10040845B2 (en) 2018-08-07
US8287870B2 (en) 2012-10-16
PE20141435A1 (es) 2014-10-22
IL238421A0 (en) 2015-06-30
US20120128692A1 (en) 2012-05-24
BRPI0916443A2 (pt) 2017-10-31
IL232861A0 (en) 2014-07-31
US20160145319A1 (en) 2016-05-26
ECSP11010827A (es) 2011-07-29
US20210087257A1 (en) 2021-03-25
EA201170205A1 (ru) 2011-08-30
CA3022196A1 (fr) 2010-01-21
DK3009449T3 (en) 2018-08-06
US9725502B2 (en) 2017-08-08
MA32561B1 (fr) 2011-08-01
CN106924729A (zh) 2017-07-07
HN2011000161A (es) 2014-06-09
SG191699A1 (en) 2013-07-31
US10414817B2 (en) 2019-09-17
US8298539B2 (en) 2012-10-30
KR20110052585A (ko) 2011-05-18
US20140205615A1 (en) 2014-07-24
WO2010007533A9 (fr) 2017-08-10
US20130302350A1 (en) 2013-11-14
PT3009449T (pt) 2018-09-28
DK2352759T3 (en) 2017-12-18
US9365636B1 (en) 2016-06-14
EP3009449B1 (fr) 2018-06-06
US20140193428A1 (en) 2014-07-10
US9127049B2 (en) 2015-09-08
IL232865A0 (en) 2014-07-31
IL232862A (en) 2016-06-30
US8124093B2 (en) 2012-02-28
PL2352759T3 (pl) 2018-04-30
UA106354C2 (ru) 2014-08-26
GT201100011CA (es) 2017-09-14
CU23953B1 (es) 2013-10-29
WO2010007533A2 (fr) 2010-01-21
IL210356A (en) 2015-06-30
JP5422649B2 (ja) 2014-02-19
ECSP11010826A (es) 2011-07-29
US20200017575A1 (en) 2020-01-16
US9371372B2 (en) 2016-06-21
US9491906B2 (en) 2016-11-15
IL232864A0 (en) 2014-07-31
CN102203133B (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
GT201100011DA (es) Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos
GT200900188A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso.
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CO6531481A2 (es) Proteinas de enlace al antigeno il-23 humanas
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos
BR112012030479A2 (pt) terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
ECSP15025845A (es) Anticuerpos anti-ceacam5 y usos de éstos
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201590115A1 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
HN2012001846A (es) Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
WO2014026768A8 (fr) Marqueurs de cancer colorectal
TR201907907T4 (tr) Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.
WO2011097327A3 (fr) Compositions et procédés de modulation de protéines tyrosine kinases récepteurs
EP2560674A4 (fr) Nanoparticule ciblant l'ischémie à des fins d'imagerie et de traitement
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana